3rd Quarter - Report — SOLVAY PHARMACEUTICALS, INC. for SOLVAY PHARMACEUTICALS INC (2008)

Firm

SOLVAY PHARMACEUTICALS, INC.

Client

SOLVAY PHARMACEUTICALS INC

Income

—

Expenses

$60,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Implementation of national strategy to prepare for pandemic influenza FY 2009 Labor, HHS appropriations bill - S. 3230

Lobbyist	Covered position, as disclosed
PATROSKI LAWSON	—

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3230 (110th)

Medicare/Medicaid MMM

Formulary requirements for certain classes of drugs. s 3101

Lobbyist	Covered position, as disclosed
PATROSKI LAWSON	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Extension of the research and development tax credit H.R. 6049 H.R. 1424 S. 3125, S 2886, S 3335

Lobbyist	Covered position, as disclosed
PATROSKI LAWSON	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1424 (110th), S. 3125 (110th), H.R. 6049 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.